Medical editing of this article was provided by Scientific Publications, Research Medical Library, The University of Texas MD Anderson Cancer Center.
Darvin P, Toor SM, Sasidharan Nair V, et al.. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11.
Bayle A, Khettab M, Lucibello F, et al.. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Ann Oncol 2020;31:959–961.
Marin-Acevedo JA, Soyano AE, Dholaria B, et al.. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol 2018;11:8.
Singh BP, Marshall JL, He AR. Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist 2020;25:197–202.
Abu-Sbeih H, Ali FS, Naqash AR, et al.. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 2019;37:2738–2745.
Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25–32.
Abu-Sbeih H, Ali FS, Wang X, et al.. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93.
Som A, Mandaliya R, Alsaadi D, et al.. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 2019;7:405–418.
Wang Y, Abu-Sbeih H, Mao E, et al.. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695–1705.
Wang Y, Abu-Sbeih H, Mao E, et al.. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018;6:37.
Abu-Sbeih H, Ali FS, Qiao W, et al.. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 2019;68:553–561.
Wang Y, Wiesnoski DH, Helmink BA, et al.. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018;24:1804–1808.
Abu-Sbeih H, Tang T, Ali FS, et al.. The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 2018;1:7–18.
Fujii Y, Nishikawa Y, Nomura M, et al.. Readministration of nivolumab after persistent immune-related colitis in a patient with recurrent melanoma. Intern Med 2018;57:1173–1176.
Johnson DH, Zobniw CM, Trinh VA, et al.. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103.
Abu-Sbeih H, Ali FS, Alsaadi D, et al.. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018;6:142.
van den Heuvel TR, Wintjens DS, Jeuring SF, et al.. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016;139:1270–1280.
Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016;22:4794–4801.
Taleban S, Elquza E, Gower-Rousseau C, et al.. Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis 2016;48:1105–1111.
Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 2018;13:1771–1775.
Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017;376:1989–1991.
Verheijden RJ, May AM, Blank CU, et al.. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res 2020;26:2268–2274.
Horvat TZ, Adel NG, Dang TO, et al.. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193–3198.
- Search Google Scholar
- Export Citation
. , Horvat TZ , Adel NG , Dang TO Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193– 3198.
The University of Texas MD Anderson Cancer Center. Evaluation and management of suspected immune-mediated colitis/diarrhea. Accessed September 10, 2020. Available at: https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf
Abu-Sbeih H, Faleck DM, Ricciuti B, et al.. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 2020;38:576–583.
Abu-Sbeih H, Ali FS, Luo W, et al.. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95.
Choi K, Abu-Sbeih H, Samdani R, et al.. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385–393.
Freedberg DE, Toussaint NC, Chen SP, et al.. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015;149:883–885.e9.
Ducarmon QR, Zwittink RD, Hornung BVH, et al.. Gut microbiota and colonization resistance against bacterial enteric infection. Microbiology and molecular biology reviews. Microbiol Mol Biol Rev 2019;83:e00007–00009.
Bonderup OK, Nielsen GL, Dall M, et al.. Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther 2018;48:618–625.
Verhaegh BP, de Vries F, Masclee AA, et al.. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016;43:1004–1013.
Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 2016;22:178.e1–178.e9.
Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med 2016;22:458–478.
Abu-Sbeih H, Herrera LN, Tang T, et al.. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019;7:242.
Chaput N, Lepage P, Coutzac C, et al.. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017;28:1368–1379.
Matson V, Fessler J, Bao R, et al.. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104–108.
Routy B, Le Chatelier E, Derosa L, et al.. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–97.